Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Objective response in our study population

From: Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

  Patient n = 148
Best response, (%)
 CR 0.6
 PR 16
 SD 54
 PD 29.4
 DCR (CR + PR + SD) 70.6
 ORR (CR + PR) 16.6